Abstract:Key Points Parkinson's disease is a progressive neurological disorder characterized primarily by motor symptoms that include rigidity, hypokinesia and tremor. The most pronounced neuropathological feature is a loss of dopaminergic neurons in the substantia nigra pars compacta, which leads to a reduction in dopamine levels in the target region, the striatum. In the substantia nigra, some neurons have intracytoplasmic inclusions known as Lewy bodies. In most patients, Parkinson's disease shows no clear inheritance and the cause of neurodegeneration is not known. Several disease mechanisms have been proposed, including oxidative stress and mitochondrial dysfunction. Some emphasis has been placed on the possibility that environmental toxins trigger these pathological changes. In the late 1990s, the discovery of the gene that causes a rare autosomal-dominant form of Parkinson's disease led to renewed interest in the search for pathogenic mechanisms. The mutated gene encodes α-synuclein, a synaptic protein of unknown function. It has been suggested that it plays a role in the recycling of vesicles that have released their neurotransmitter content into the synaptic cleft. Moreover, further rare forms of Parkinson's disease have been identified that result from mutations in parkin and ubiquitin carboxy-terminal hydrolase L1. These proteins participate in the ubiquitin–proteasome pathway, which is responsible for the degradation of unwanted proteins. We speculate why changes in these diverse genes lead to a neurodegenerative process that is relatively focused on dopamine-containing neurons, and emphasize the role of dopamine-dependent oxidative stress in this process. We believe that there are multiple aetiological triggers, resulting from either genetic changes or environmental insults, which share the same final common pathway to cell death in dopaminergic neurons. Increased levels of cytoplasmic dopamine in nigral neurons in Parkinson's disease patients might result in dopamine oxidation and the generation of reactive oxygen species that can damage and eventually kill these neurons. One pathway that might lead to these events involves impaired vesicular storage of dopamine. Recent experimental evidence shows that the expression of mutant α-synuclein in a human dopaminergic cell line increases cytoplasmic dopamine levels and raises the levels of superoxide radicals in the cytoplasm. Dopamine-induced oxidative stress, impaired synaptic vesicle function and misfolding of α-synuclein, due to mutations or to oxidative damage to this protein, might be components in a self-perpetuating vicious cycle that eventually leads to the demise of dopaminergic neurons.

Crosstalk Between Presynaptic Trafficking and Autophagy in Parkinson's Disease

The Cross-Links of Endoplasmic Reticulum Stress, Autophagy, and Neurodegeneration in Parkinson's Disease

The Cross-Links of Endoplasmic Reticulum Stress, Autophagy, and Neurodegeneration in Parkinson’s Disease

Deconvoluting the complexity of autophagy and Parkinson's disease for potential therapeutic purpose

Virulence genes of Parkinson's disease and autophagy

Defective Autophagy in Parkinson’s Disease: Lessons from Genetics

Dysfunction of Synaptic Vesicle Endocytosis in Parkinson's Disease.

Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease

Cell biology of Parkinson's disease: Mechanisms of synaptic, lysosomal, and mitochondrial dysfunction

Mitochondrial function and autophagy: integrating proteotoxic, redox, and metabolic stress in Parkinson's disease

Key genes and convergent pathogenic mechanisms in Parkinson disease

Autophagy‐regulating miRNAs: Novel therapeutic targets for Parkinson's disease (Review)

Reduced synaptic activity and dysregulated extracellular matrix pathways in midbrain neurons from Parkinson's disease patients

The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson’s disease

From Pathogenesis to Therapeutic Prospects

Dysregulation of autophagy and mitochondrial function in Parkinson's disease.

Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson's Disease

The autophagy-lysosome pathway: a potential target in the chemical and gene therapeutic strategies for Parkinson’s disease

Dysfunction of two lysosome degradation pathways of α-synuclein in Parkinson’s disease: potential therapeutic targets?

Signaling Pathways in Parkinson’s Disease: Molecular Mechanisms and Therapeutic Interventions

Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein